Neurology
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Figures Only
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow CME: Take the course for this article:
 Volume 60, Number 5, March 11, 2003
Right arrow Correspondence:
Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when Correspondence are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Wingerchuk, D. M.
Right arrow Articles by Weinshenker, B. G.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Wingerchuk, D. M.
Right arrow Articles by Weinshenker, B. G.
Related Collections
Right arrow All Health Services Research
Right arrow Outcome research
Right arrow All Demyelinating disease (CNS)
Right arrow Devic's syndrome

Neurology 2003;60:848-853
© 2003 American Academy of Neurology

Neuromyelitis optica

Clinical predictors of a relapsing course and survival

Dean M. Wingerchuk, MD FRCP(C) and Brian G. Weinshenker, MD FRCP(C)

From the Departments of Neurology, Mayo Clinic, Scottsdale, AZ (Dr. Wingerchuk) and Rochester, MN (Dr. Weinshenker).

Address correspondence and reprint requests to Dr. Dean M. Wingerchuk, Department of Neurology, Mayo Clinic, 13400 East Shea Boulevard, Scottsdale, AZ 85259; e-mail: wingerchuk.dean{at}mayo.edu

Background: The relapsing form of neuromyelitis optica (NMO) is characterized by recurrent optic neuritis and myelitis, usually leading to severe, permanent, relapse-related neurologic impairment (e.g., blindness, paraplegia) within 5 years. Aggressive therapy aimed at relapse prevention initiated soon after disease onset may be expected to have a relatively greater impact on early relapse-related disability in NMO than in typical MS. Early prediction of a relapsing course and subsequent disease severity would facilitate design and implementation of clinical trials of such therapies.

Methods: A database of clinical and laboratory features of patients with NMO (n = 80) was used to develop potentially useful models predictive of a relapsing disease course and of subsequent disease severity as measured by survival.

Results: Predictors of a relapsing course were longer interattack interval between the first two clinical events (rate ratio [RR] = 2.16; per month increase), older age at onset (RR = 1.08; per year increase), female sex (RR = 10.0, female vs male), and less severe motor impairment with the sentinel myelitis event (RR = 0.48; per severity scale point increase). A history of other autoimmune disease (RR = 4.15; presence vs absence), higher attack frequency during the first 2 years of disease (RR = 1.21; per attack), and better motor recovery following the index myelitis event (RR = 1.84; per point increase) were associated with mortality due to relapsing NMO.

Conclusions: These predictive models identify several clinical features, each available at diagnosis or early in the disease course, that predict relapsing disease and survival. These results may be useful to identify patients at high risk for severe, relapsing neuromyelitis optica in order to initiate early therapy for relapse prevention and to design clinical trials to study such interventions.




This article has been cited by other articles:


Home page
 IOVSHome page
H. Merle, S. Olindo, A. Donnio, R. Richer, D. Smadja, and P. Cabre
Retinal Peripapillary Nerve Fiber Layer Thickness in Neuromyelitis Optica
Invest. Ophthalmol. Vis. Sci., October 1, 2008; 49(10): 4412 - 4417.
[Abstract] [Full Text] [PDF]

Home page
 Mult SclerHome page
A Javed, R Balabanov, B. Arnason, T. Kelly, N. Sweiss, P Pytel, R Walsh, E. Blair, A Stemer, M Lazzaro, et al.
Minor salivary gland inflammation in Devic's disease and longitudinally extensive myelitis
Multiple Sclerosis, July 1, 2008; 14(6): 809 - 814.
[Abstract] [PDF]

Home page
 NeurologyHome page
B. Banwell, S. Tenembaum, V. A. Lennon, E. Ursell, J. Kennedy, A. Bar-Or, B. G. Weinshenker, C. F. Lucchinetti, and S. J. Pittock
Neuromyelitis optica-IgG in childhood inflammatory demyelinating CNS disorders
Neurology, January 29, 2008; 70(5): 344 - 352.
[Abstract] [Full Text] [PDF]

Home page
 RadiologyHome page
C. S. Yu, C. Z. Zhu, K. C. Li, Y. Xuan, W. Qin, H. Sun, and P. Chan
Relapsing Neuromyelitis Optica and Relapsing-Remitting Multiple Sclerosis: Differentiation at Diffusion-Tensor MR Imaging of Corpus Callosum
Radiology, July 1, 2007; 244(1): 249 - 256.
[Abstract] [Full Text] [PDF]

Home page
 Arch NeurolHome page
B. G. Weinshenker
Neuromyelitis Optica Is Distinct From Multiple Sclerosis
Arch Neurol, June 1, 2007; 64(6): 899 - 901.
[Full Text] [PDF]

Home page
 Arch NeurolHome page
S. L. Galetta and J. Bennett
Neuromyelitis Optica Is a Variant of Multiple Sclerosis
Arch Neurol, June 1, 2007; 64(6): 901 - 903.
[Full Text] [PDF]

Home page
 NeurologyHome page
L. B. Krupp, B. Banwell, S. Tenembaum, and for the International Pediatric MS Study Group
Consensus definitions proposed for pediatric multiple sclerosis and related disorders
Neurology, April 17, 2007; 68(16_suppl_2): S7 - S12.
[Abstract] [Full Text] [PDF]

Home page
 NeurologyHome page
B. Banwell, M. Shroff, J. M. Ness, D. Jeffery, S. Schwid, B. Weinstock-Guttman, and for the International Pediatric MS Study Group
MRI features of pediatric multiple sclerosis
Neurology, April 17, 2007; 68(16_suppl_2): S46 - S53.
[Abstract] [Full Text] [PDF]

Home page
 NeurologyHome page
M. Wilejto, M. Shroff, J. R. Buncic, J. Kennedy, C. Goia, and B. Banwell
The clinical features, MRI findings, and outcome of optic neuritis in children.
Neurology, July 25, 2006; 67(2): 258 - 262.
[Abstract] [Full Text] [PDF]

Home page
 Rheumatology (Oxford)Home page
F. Falcini, S. Trapani, L. Ricci, M. Resti, G. Simonini, and M. de Martino
Sustained improvement of a girl affected with Devic's disease over 2 years of mycophenolate mofetil treatment
Rheumatology, July 1, 2006; 45(7): 913 - 915.
[Full Text] [PDF]

Home page
 Am. J. Neuroradiol.Home page
C.S. Yu, F.C. Lin, K.C. Li, T.Z. Jiang, C.Z. Zhu, W. Qin, H. Sun, and P. Chan
Diffusion tensor imaging in the assessment of normal-appearing brain tissue damage in relapsing neuromyelitis optica.
AJNR Am. J. Neuroradiol., May 1, 2006; 27(5): 1009 - 1015.
[Abstract] [Full Text] [PDF]

Home page
 Mult SclerHome page
A. Y Poppe, Y. Lapierre, D. Melancon, D. Lowden, L. Wardell, L. M Fullerton, and A. Bar-Or
Neuromyelitis optica with hypothalamic involvement
Multiple Sclerosis, October 1, 2005; 11(5): 617 - 621.
[Abstract] [PDF]

Home page
 JEMHome page
V. A. Lennon, T. J. Kryzer, S. J. Pittock, A.S. Verkman, and S. R. Hinson
IgG marker of optic-spinal multiple sclerosis binds to the aquaporin-4 water channel
J. Exp. Med., August 15, 2005; 202(4): 473 - 477.
[Abstract] [Full Text] [PDF]

Home page
 J. Neurol. Neurosurg. PsychiatryHome page
S Jacob, M Zarei, A Kenton, and H Allroggen
Gluten sensitivity and neuromyelitis optica: two case reports
J. Neurol. Neurosurg. Psychiatry, July 1, 2005; 76(7): 1028 - 1030.
[Abstract] [Full Text] [PDF]

Home page
 NeurologyHome page
J. Correale and M. Fiol
Activation of humoral immunity and eosinophils in neuromyelitis optica
Neurology, December 28, 2004; 63(12): 2363 - 2370.
[Abstract] [Full Text] [PDF]

Home page
 Mult SclerHome page
S Pradhan and V N Mishra
A central demyelinating disease with atypical features
Multiple Sclerosis, June 1, 2004; 10(3): 308 - 315.
[Abstract] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2003 by AAN Enterprises, Inc.